{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-097657","form_type":"8-K","ticker":"BDX","cik":"0000010795","company_name":"BECTON DICKINSON & CO","filed_at":"2022-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.656287+00:00","generated_at":"2026-06-26T09:00:07.377416+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BD completes spinoff of Diabetes Care business as Embecta Corp. (EMBC)","bullets":["Shareholders receive one share of embecta for every five BD shares held as of March 22, 2022.","BD retains no ownership; embecta begins trading on NASDAQ under ticker EMBC.","Two BD directors (Claire Pomeroy, David Melcher) resign to join embecta board; BD board reduced to 11.","embecta issued $200M 6.750% senior secured notes due 2030 to BD; BD exchanged for $199M floating-rate notes.","BD guaranteed embecta credit facility and senior notes; guarantee automatically released upon separation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-097657","json":"https://secwatch.observer/filing/0001193125-22-097657.json","markdown":"https://secwatch.observer/filing/0001193125-22-097657.md","text":"https://secwatch.observer/filing/0001193125-22-097657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10795/000119312522097657/0001193125-22-097657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10795/000119312522097657/d328383d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T09:00:07.377416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13d96b708b","claim":"Claire Pomeroy resigned as director at BECTON DICKINSON & CO.","evidence_excerpt":"each of Claire Pomeroy, MD and David F. Melcher has resigned as directors of BD, in each case effective as of April 1, 2022, in connection with the completion of the Separation and the Distribution and their appointment to the board of directors of embecta.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10795/000119312522097657/0001193125-22-097657-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"ad0bcf93c3","claim":"David Melcher resigned as director at BECTON DICKINSON & CO.","evidence_excerpt":"each of Claire Pomeroy, MD and David F. Melcher has resigned as directors of BD, in each case effective as of April 1, 2022, in connection with the completion of the Separation and the Distribution and their appointment to the board of directors of embecta.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10795/000119312522097657/0001193125-22-097657-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}